What the Wegovy Pill Costs per Month
Self-pay through the manufacturer's own pharmacy, the Wegovy pill cost depends on your dose rather than a single headline figure: $149 a month at the 1.5 mg starting dose, $199 at 4 mg, and $299 at both 9 mg and the 25 mg maintenance dose, where a month represents one bottle of 30 tablets. Because the prescribing label escalates the dosage every 30 days, your first three months cost less than the long-term maintenance dose you settle on. A separate savings offer advertises paying as little as $25 a month, capped at $100 of savings a month for up to 3 months, with government beneficiaries excluded. For Medicare beneficiaries, the Wegovy pill is on the eligible drug list for the Centers for Medicare & Medicaid Services (CMS) Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge, a demonstration running from 1 July 2026 to 31 December 2027 with a $50 copay. Novo Nordisk publishes no effective date for these self-pay prices on its pharmacy portal and can change or cancel the programs at any time, which means every figure must be verified directly through NovoCare Pharmacy before filling a prescription.
The Verdict
| Dose | Published self-pay price per month | Where it falls in treatment |
|---|---|---|
| 1.5 mg | $149 | Days 1 to 30 (recommended starting escalation dose) |
| 4 mg | $199 | Days 31 to 60 (second escalation step) |
| 9 mg | $299 | Days 61 to 90 (third escalation step) |
| 25 mg | $299 | Day 91 onward (recommended maintenance dose) |
Why the First Three Months Cost Less
The prescribing information approved by the Food and Drug Administration (FDA) requires a stepped dosage titration that changes what you pay during initiation. Table 2 of the label specifies that patients start at 1.5 mg daily for days 1 to 30, increase to 4 mg daily for days 31 to 60, advance to 9 mg daily for days 61 to 90, and reach the 25 mg maintenance dose on day 91. Because Novo Nordisk prices the oral formulation by tablet strength through NovoCare Pharmacy, the cost of initiating therapy is lower than the ongoing cost of staying on treatment.
Adding up the published monthly prices for the escalation schedule yields a clear baseline for your first three months:
- Month 1 (days 1 to 30, 1.5 mg): $149 for a bottle of 30 tablets
- Month 2 (days 31 to 60, 4 mg): $199 for a bottle of 30 tablets
- Month 3 (days 61 to 90, 9 mg): $299 for a bottle of 30 tablets
Summing these three published figures results in $647 for the full 90-day escalation period. Once you reach the 25 mg daily maintenance dose on day 91, treatment costs $299 for each subsequent 30-day bottle at published self-pay rates. This arithmetic reflects adding three individual monthly prices published on the manufacturer's pharmacy page rather than a pre-paid package or bundled rate. Novo Nordisk publishes no effective date for these figures and reserves the right to modify or cancel the pricing schedule at any time. In addition, the prescribing information states that if a patient does not tolerate a specific dose during escalation, the prescriber may consider delaying dosage escalation. Any extension of time spent at 1.5 mg or 4 mg keeps your monthly spending at $149 or $199 for an additional 30-day cycle before you advance to the $299 tier.
What a Month Actually Buys
A monthly fill of the Wegovy pill provides exactly one bottle containing 30 oral tablets. The prescribing information mandates taking one tablet orally once daily in the morning on an empty stomach with up to 4 ounces of plain water. Patients must not swallow the tablet with liquids other than water, and the label directs patients to swallow tablets whole without splitting, crushing, chewing, or dissolving them. The label explicitly instructs patients not to take more than one tablet per day.
After swallowing the tablet, you must wait at least 30 minutes before eating, drinking, or taking other oral medications. These administration constraints stem directly from the underlying pharmacology of oral semaglutide, which exhibits an absolute bioavailability of roughly 1% to 2%, compared to 89% for subcutaneous injections. Maximum concentration in the bloodstream is reached about 1 hour after taking an oral tablet, versus 1 to 3 days after an injection.
Because each bottle contains exactly 30 tablets for a 30-day cycle, there is zero surplus medication in a standard monthly fill. If you miss a dose, the prescribing information instructs you to skip the missed dose and take the next dose the following day as scheduled. Patients should not double up or take extra tablets to compensate for a missed morning. Managing your schedule according to the label means one bottle of 30 tablets covers 30 days of once-daily dosing.
The Savings Offer and Its Limits
Alongside its standard self-pay rates, NovoCare Pharmacy lists an advertised savings program stating that eligible individuals can pay as little as $25 per month. However, the fine print published by the manufacturer establishes a strict limitation: savings are subject to a maximum savings cap of $100 per month, and the offer is listed for up to 3 months only. Furthermore, the offer explicitly excludes government healthcare beneficiaries.
The manufacturer's pharmacy page notes that eligibility and restrictions apply, but it does not publish the specific eligibility criteria or qualifying insurance terms on that portal. To confirm whether you qualify for the savings card, you must review the detailed requirements directly on the NovoCare Pharmacy portal. Patients should also keep in mind that Novo Nordisk can modify or discontinue the savings offer at any time.
Medicare and the GLP-1 Bridge
Medicare beneficiaries navigate a different pricing structure through a formal demonstration run by CMS called the Medicare GLP-1 Bridge. The demonstration runs between 1 July 2026 and 31 December 2027. Under this federal program, eligible Medicare beneficiaries have a fixed $50 copay for covered weight-management medications. CMS published an eligible-drug list that explicitly names the Wegovy pill, alongside Wegovy injection, Foundayo, and Zepbound in the KwikPen formulation only. Single-dose vial and single-dose pen formulations of Zepbound are excluded from the eligible list.
The Medicare GLP-1 Bridge operates outside the standard Part D benefit design, which introduces three distinct financial consequences that differ from normal prescription fills:
- The standard Medicare Part D deductible does not apply to medications filled under the demonstration.
- No part of the $50 copay counts towards the beneficiary's True Out-of-Pocket (TrOOP) threshold.
- There is no Low-Income Subsidy (LIS) provided for LIS beneficiaries under this demonstration.
The demonstration page published by CMS does not outline the complete beneficiary eligibility requirements, or clinical qualifications. Instead, CMS instructs beneficiaries to visit Medicare.gov/glp1bridge to learn whether they qualify, and to discuss treatment with their doctor. Coverage outside of this specific demonstration depends entirely on your individual plan formulary. Whether Medicare covers the Wegovy pill for your specific medical history cannot be stated in advance, making direct plan verification essential.
What the Pill Costs against the Pen
Comparing published manufacturer prices reveals notable differences between oral tablets and weekly subcutaneous injections. On the NovoCare Pharmacy self-pay portal, Wegovy injection pens are listed at $199 per month for 0.25 mg and 0.5 mg for patients new to the Wegovy Savings Offer and NovoCare Pharmacy, valid for 2 monthly fills through 31 December 2026. Following those initial two fills, the published price rises to $349 per month for all standard injection doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. The higher-dose Wegovy HD 7.2 mg injection is listed at $399 per month. A monthly fill for the injection consists of one box containing 4 pens, compared to one bottle of 30 tablets for the oral pill.
At the recommended long-term maintenance doses, the Wegovy pill at 25 mg is priced at $299 per month, while the Wegovy 2.4 mg injection is listed at $349 per month under standard self-pay terms. Both formulations are included on the CMS eligible-drug list for the Medicare GLP-1 Bridge demonstration at the same $50 monthly copay. The two forms also differ in how quickly patients escalate to maintenance: the injection reaches 2.4 mg after 16 weeks of stepped titration (at week 17), whereas the pill reaches 25 mg on day 91 after 90 days of daily titration. For an in-depth breakdown of practical administration and dosing differences, see our comparison of the Wegovy pill vs injection.
Several figures people search for are not quoted on this page, because the manufacturer's own pharmacy page does not publish them. The manufacturer's pharmacy page carries no standard retail list price, no walk-in pharmacy cash price, no commercial copay benchmark and no compounded-semaglutide price, so none is quoted here. Commercial insurance coverage and copayment tiers depend entirely on employer benefit designs and individual commercial health plan formularies, which you must confirm directly with your insurer.
Related Clinical and Dosing Context
Evaluating the true expense of oral semaglutide requires understanding its clinical indications and daily administration protocol. Novo Nordisk announced the FDA approval of the Wegovy pill on 22 December 2025, and the pill is indicated alongside a reduced-calorie diet and increased physical activity to reduce excess body weight in adults with obesity or overweight with at least one comorbid condition, and to reduce Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with established cardiovascular disease and obesity or overweight. Unlike the injection, the pill does not carry indications for pediatric patients aged 12 and older or for noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH). To explore how oral semaglutide functions, review our guide to the Wegovy pill, read our practical instructions on how to take the Wegovy pill, inspect the differences in Wegovy pill vs Rybelsus, and examine trial evidence on semaglutide side effects. Before starting treatment, consult a licensed healthcare professional to evaluate your medical history.
Frequently Asked Questions
How much does the Wegovy pill cost per month?
Self-pay pricing through NovoCare Pharmacy depends on your dose: $149 per month for the 1.5 mg starting dose, $199 per month for 4 mg, and $299 per month for both 9 mg and the 25 mg maintenance dose. One month provides a single bottle of 30 tablets. A separate savings offer advertises paying as little as $25 per month, subject to a $100 monthly cap for up to 3 months, with government beneficiaries excluded. Eligible Medicare beneficiaries participating in the CMS Medicare GLP-1 Bridge demonstration pay a $50 copay through 31 December 2027. Novo Nordisk can modify self-pay pricing at any time.
Is the Wegovy pill covered by insurance?
Commercial insurance coverage for the Wegovy pill depends entirely on your employer benefit design and specific plan formulary. Commercial copay amounts, coverage percentages and prior-authorization criteria are not published on the manufacturer's pharmacy page, and they vary by plan. Government healthcare beneficiaries face different rules, such as the temporary Medicare GLP-1 Bridge demonstration. To determine whether your prescription is covered and what your copay will be, contact your health insurance provider directly and request formulary tier details for oral semaglutide tablets.
Is the Wegovy pill covered by Medicare?
Standard Medicare Part D coverage depends on your specific plan formulary, but the Wegovy pill is explicitly listed as eligible under the CMS Medicare GLP-1 Bridge demonstration running from 1 July 2026 to 31 December 2027. Eligible beneficiaries enrolled in the demonstration pay a $50 monthly copay. However, CMS does not publish the complete beneficiary eligibility requirements on its public announcement page. In addition, demonstration copays do not count toward your Part D True Out-of-Pocket cap. You must check your eligibility at Medicare.gov/glp1bridge and consult your prescribing physician to confirm coverage.
Is the Wegovy pill cheaper than the Wegovy injection?
At maintenance doses, published self-pay pricing for the Wegovy pill is lower than standard self-pay pricing for the injection. On NovoCare Pharmacy, the 25 mg daily maintenance tablet is listed at $299 per month, while the 2.4 mg weekly injection is listed at $349 per month after an initial introductory period. For starting doses, the 1.5 mg pill costs $149 per month, whereas introductory injection pens are listed at $199 per month for the first two fills. Under the CMS Medicare GLP-1 Bridge demonstration, both formulations carry the identical $50 monthly copay for eligible beneficiaries.
Does the Wegovy pill cost more at the maintenance dose?
Yes, the Wegovy pill costs more at the maintenance dose than during the initial escalation steps under self-pay pricing. Table 2 of the FDA label outlines a 90-day titration schedule starting at 1.5 mg daily ($149 per month) for days 1 to 30, stepping up to 4 mg daily ($199 per month) for days 31 to 60, and advancing to 9 mg daily ($299 per month) for days 61 to 90. From day 91 onward, patients take the 25 mg daily maintenance dose, which remains at $299 per month on NovoCare Pharmacy.
Can I use a copay savings card with Medicare?
The savings offer excludes government beneficiaries, as published on the manufacturer's pharmacy page. The terms published on NovoCare Pharmacy explicitly state that government beneficiaries are excluded from the savings offer. The CMS Medicare GLP-1 Bridge demonstration is a separate pathway, with a $50 copay, running to 31 December 2027; CMS does not publish its eligibility conditions, so check Medicare.gov/glp1bridge and your own plan. Check Medicare.gov/glp1bridge and discuss coverage options directly with your prescribing physician to determine your eligibility.
Will the Wegovy pill price change?
Yes, published prices can change at any time. NovoCare Pharmacy does not list an effective or expiration date for its self-pay rates, and Novo Nordisk explicitly states that it reserves the right to modify or cancel its pricing and savings programs at any time. Similarly, the federal CMS Medicare GLP-1 Bridge demonstration has a defined expiration date of 31 December 2027. Because prices and manufacturer terms are subject to revision, always verify the latest self-pay pricing directly on NovoCare Pharmacy before filling or renewing your prescription.